AG-1557
98%
- Product Code: 99436
CAS:
189290-58-2
| Molecular Weight: | 407.21 g./mol | Molecular Formula: | C₁₆H₁₄IN₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
AG-1557 is primarily utilized in research settings as a selective inhibitor of protein kinase C (PKC). Its application is significant in studying cellular signaling pathways, particularly those involved in cell growth, differentiation, and apoptosis. Researchers employ AG-1557 to investigate the role of PKC in various diseases, including cancer, cardiovascular disorders, and neurological conditions. By inhibiting PKC, it helps in understanding the molecular mechanisms underlying these diseases and aids in the development of targeted therapies. Additionally, AG-1557 is used in pharmacological studies to explore potential therapeutic interventions and to assess the efficacy of PKC inhibitors in preclinical models.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $48.60 |
+
-
|
| 0.005 | 10-20 days | $218.72 |
+
-
|
AG-1557
AG-1557 is primarily utilized in research settings as a selective inhibitor of protein kinase C (PKC). Its application is significant in studying cellular signaling pathways, particularly those involved in cell growth, differentiation, and apoptosis. Researchers employ AG-1557 to investigate the role of PKC in various diseases, including cancer, cardiovascular disorders, and neurological conditions. By inhibiting PKC, it helps in understanding the molecular mechanisms underlying these diseases and aids in the development of targeted therapies. Additionally, AG-1557 is used in pharmacological studies to explore potential therapeutic interventions and to assess the efficacy of PKC inhibitors in preclinical models.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :